Given the importance of the activation of immune effector cells to eliminate cancer, a number of immunotherapies, such as programmed cell death 1 (PD-1) blockade, chimeric antigen receptor (CAR) T cells, and T cell–engaging antibodies, have been evaluated and been FDA approved in several types of cancer, including lymphoma (10–13). Here, PDCD1 is linked to cancer.